Previous 10 | Next 10 |
The following slide deck was published by Iovance Biotherapeutics, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Iovance Biotherapeutics, Inc. 2022 Q1 - Results - Earnings Call Presentation
Iovance Biotherapeutics, Inc. (IOVA) Q1 2022 Results Conference Call May 05, 2022 04:30 PM ET Company Participants Sara Pellegrino - Vice President, Investor and Public Relations Dr. Fred Vogt - Interim President and Chief Executive Officer Dr. Igor Bilinsky - Chief Operating Officer Jim Zieg...
Iovance Biotherapeutics press release (NASDAQ:IOVA): Q1 GAAP EPS of -$0.58 beats by $0.06. Cash position of $516.0 million at March 31, 2022 is expected to be sufficient into 2024. For further details see: Iovance Biotherapeutics GAAP EPS of -$0.58 beats by $0.06
SAN CARLOS, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL), today reported first quarter...
Iovance Biotherapeutics (NASDAQ:IOVA) is scheduled to announce Q1 earnings results on Thursday, May 5, after market close. The consensus EPS estimate is -$0.63. Over the last 1 year, IOVA has beaten EPS estimates 50% of the time and has beaten revenue estimates 25% of the time. Over the last ...
The overall price growth since the inception of IDNA is quite impressive, considering the huge impact of the Covid-19 pandemic in the U.S. equity market. Huge price loss in the past 12 months, but positive price gain in the past three years, is an apparently visible trend in Genomics-...
SAN CARLOS, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that translational data for lifileucel in patients with metastatic melanoma will be h...
SAN CARLOS, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its first quarter financial results on Thursday, May 5, 2022. Management will host a conf...
SAN CARLOS, Calif., April 25, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that senior leadership plans to present at the following conference: Charda...
Clovis, a "trading stock," has some shakiness in its fundamentals. Moreover, the shares tend to rise and fall for you to trade for short-term gains. Due to upcoming catalysts in June, Clovis is a trading stock that is about to embark on another bullish cycle. Despite being a tradi...
News, Short Squeeze, Breakout and More Instantly...
Iovance Biotherapeutics Inc. Company Name:
IOVA Stock Symbol:
NASDAQ Market:
Iovance Biotherapeutics Inc. Website:
2024-07-26 10:45:04 ET Pacific Biosciences of California Inc (PACB) PACB is trading UP for the last 5 days, and it at trading at $2.10 with volume of 3,952,245 and a one day change of $0.19 (9.97%). Pacific Biosciences of California Inc has a 52-week low of 1.16 and a 52-week high o...
2024-07-14 05:45:00 ET Biotech stocks like Iovance Biotherapeutics (NASDAQ: IOVA) often look appealing because they could experience enormous growth in relatively short periods of time. Plus, over the long term, successful biotech companies have the opportunity to blossom into large...